Overview

A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies

Status:
RECRUITING
Trial end date:
2028-03-15
Target enrollment:
Participant gender:
Summary
Evaluation of the safety, tolerability, pharmacokinetics, and preliminary efficacy of XS-04 in patients with relapsed or refractory hematologic malignancies
Phase:
PHASE1
Details
Lead Sponsor:
NovaOnco Therapeutics Co., Ltd.